Press Release

AB-Therapeutics Hires José Alfón as Director of Development

Alfón, previously at Palau Pharma, will head the Catalan company’s R&D

January 3, 2011

The Catalan biotechnology company AB-Therapeutics, that focuses on drug development, has just hired José Alfón as Director of Development. Alfón previously served as Drug Development Project Leader at Palau Pharma.

In bringing Alfón aboard, AB-Therapeutics has finished putting together a solid team of scientists with broad international experience. His mission will be to direct the company’s recently begun preclinical development program for an anti-cancer drug candidate through the clinical phase.

José Alfón, 43, earned a Bachelor of Pharmacy and an MS in Pharmaceutical Sciences from the Hebrew University of Jerusalem, and a PhD in Pharmaceutical Sciences from the University of Barcelona (UB). He has over ten years experience in identifying drug candidates and in developing drugs from the discovery stage to Phase II clinical trials. In addition to Palau Pharma, where has spent most of his career to date, he has also held various research positions at the Hebrew University of Jerusalem, the Spanish National Research Council (CSIC), and different hospitals in the UK and Israel.

ABOUT AB-THERAPEUTICS

AB-Therapeutics, SL is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).

AB-Therapeutics, SL develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a molecule ready to start preclinical development in 4Q2010, with Phase I clinical trials (first in man) starting in late 2011 / early 2012. A second drug candidate will start preclinical development in 2Q2011.

Contact:
 
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
 
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com

LATEST NEWS

05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

Press Release

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

Press Release

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

Press Release

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG